Small ingredients.
Different jobs.

Design: 50 white women with facial photoaging used 5% niacinamide on one half-face and its vehicle on the other, twice daily for 12 weeks. Side allocation was randomized and double-blind; assessments occurred at baseline and four-week intervals.

Finding: the primary abstract reports significant reductions in fine lines/wrinkles, hyperpigmented spots, red blotchiness and yellowing, with improved instrument-measured elasticity. Exact group means and variability are not supplied in the retrieved abstract, so this page does not invent a percentage improvement.

Limitations: a small, selected population and one formulation. Authors were Procter & Gamble employees and the company funded the work. It does not establish the best concentration, lifelong benefit or a result in all skin types. [2]

The publication combined laboratory experiments with two human investigations: 18 people with hyperpigmentation in a paired 5% moisturizer-versus-vehicle study, and 120 people with facial tanning assigned to two of three treatments: vehicle, sunscreen, or 2% niacinamide plus sunscreen.

The abstract reports reduced hyperpigmentation and greater skin lightness versus vehicle after four weeks. The sunscreen-containing arm is not isolated niacinamide efficacy. The laboratory pigment-transfer result must not be read as a percentage reduction in human dark spots. Full numerical clinical tables were not retrieved; the paper has industry-affiliated authors. [1]

Twenty-seven women used 4% niacinamide cream on one half-face and 4% hydroquinone on the other for eight weeks in a randomized, double-blind trial with SPF 50+ sunscreen. Both sides improved. Colorimetric lightness did not differ statistically between treatments; physician-rated good-to-excellent improvement was less frequent with niacinamide.

A nonsignificant difference in a small trial does not establish equivalence to hydroquinone. There was no vehicle-only arm. The full text also reports that reduced solar elastosis in the biopsy subset was not statistically significant, despite the more favorable abstract language. Some printed MASI confidence intervals are internally inconsistent; they are not charted here.

Five participants had side effects on the niacinamide side versus eight on the hydroquinone side, most commonly redness, itching or burning. This short trial cannot establish long-term safety. Melasma is a clinical condition, not a diagnosis to make from a cosmetic product page. [3]

Seventy-six women aged 30–60 with periocular wrinkles tested one of five 0.1% HA formulations (50, 130, 300, 800 or 2000 kDa) twice daily for 60 days, with vehicle cream around the other eye. Hydration, elasticity and wrinkle replicas were assessed at baseline, day 30 and day 60. The 76 participants were distributed across formulations, not 76 per molecular-weight group.

The abstract reports improved hydration and overall elasticity versus vehicle across all tested HA creams. Significant wrinkle-depth improvements at day 60 were reported for the 50 and 130 kDa groups, not uniformly for all five sizes. Exact endpoint-specific group sizes and numerical outcome means are not in the retrieved abstract.

The findings support a size-and-formulation-dependent cosmetic effect, not a general filler-like result. The publication includes ingredient-industry affiliations. A sodium-hyaluronate label with no molecular weight cannot be matched to either favorable low-molecular-weight arm. [6]

Forty women completed six weeks of twice-daily PCA Skin Hyaluronic Acid Boosting Serum, with sunscreen. Corneometry, investigator appearance scores and tolerability were assessed; visits included immediate post-application measurement and weeks 2, 4 and 6.

Hydration and several appearance scores improved from baseline, and tolerability was favorable. However, there was no randomized vehicle comparison. The serum included proprietary co-actives, not isolated HA, and active concentrations were not disclosed. These changes cannot be assigned to HA alone or transferred to Neurogan’s scalp formula.

The skin-surface sampling methods specify a subset of 15, whereas a figure caption describes 40; this page does not visualize that subset endpoint. The study and publication fee were funded by Colgate-Palmolive, with company employees among the authors. [7]

This primary report evaluated a high-molecular-weight HA formulation with peptides, used twice daily with cleanser and SPF 30+. Follow-up visits occurred at weeks 2, 4 and 8; the four-month calendar window is not four months of treatment per participant.

The abstract reports improved hydration and investigator-rated skin texture and dryness versus baseline. It is an open-label study, not a vehicle-controlled demonstration of HA alone. The overall clinical denominator is absent from the retrieved abstract; the seven-person biopsy subset must not be treated as the main sample. No quantitative efficacy chart is drawn from it. The publication identifies Alastin Skincare copyright. [8]

Follow the finished product’s directions rather than copying experimental concentrations. Try a small area first; a home patch test cannot exclude later allergy. Introduce products gradually, avoid eyes and broken skin, and discontinue if irritation persists. Ingredient tolerability in a short trial cannot predict every user’s reaction to a blend.

Sun protection remains important when evaluating pigmentation. Persistent discoloration, inflamed or scaling scalp, and hair loss may need diagnosis rather than more cosmetic actives. Discuss use during pregnancy, breastfeeding or treatment of a skin condition with a qualified clinician; the trials here do not establish safety in those groups.

Hydration is not collagen replacement. A cultured hair follicle is not a clinical regrowth result. A combination result is not isolated-ingredient efficacy. No cited study tests either current Neurogan formula.